These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

564 related items for PubMed ID: 25865094

  • 1. Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.
    Garnacho-Montero J, Amaya-Villar R, Ferrándiz-Millón C, Díaz-Martín A, López-Sánchez JM, Gutiérrez-Pizarraya A.
    Expert Rev Anti Infect Ther; 2015 Jun; 13(6):769-77. PubMed ID: 25865094
    [Abstract] [Full Text] [Related]

  • 2. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
    Karaoglan I, Zer Y, Bosnak VK, Mete AO, Namiduru M.
    J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
    [Abstract] [Full Text] [Related]

  • 3. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
    Liu CP, Shih SC, Wang NY, Wu AY, Sun FJ, Chow SF, Chen TL, Yan TR.
    J Microbiol Immunol Infect; 2016 Dec; 49(6):934-940. PubMed ID: 25553994
    [Abstract] [Full Text] [Related]

  • 4. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study.
    Lee NY, Wang CL, Chuang YC, Yu WL, Lee HC, Chang CM, Wang LR, Ko WC.
    Pharmacotherapy; 2007 Nov; 27(11):1506-11. PubMed ID: 17963460
    [Abstract] [Full Text] [Related]

  • 5. Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome.
    Kim NH, Hwang JH, Song KH, Choe PG, Kim ES, Park SW, Kim HB, Kim NJ, Park WB, Oh MD.
    Scand J Infect Dis; 2013 Apr; 45(4):315-9. PubMed ID: 23113680
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
    Jean SS, Hsieh TC, Hsu CW, Lee WS, Bai KJ, Lam C.
    J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
    [Abstract] [Full Text] [Related]

  • 7. OXA-type Carbapenemases and Susceptibility of Colistin and Tigecycline Among Carbapenem-Resistant Acinetobacter Baumannii Isolates from Patients with Bacteremia in Turkey.
    Cakirlar FK, Ciftci IH, Gonullu N.
    Clin Lab; 2015 Dec; 61(7):741-7. PubMed ID: 26299073
    [Abstract] [Full Text] [Related]

  • 8. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU.
    Sheng WH, Wang JT, Li SY, Lin YC, Cheng A, Chen YC, Chang SC.
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):380-6. PubMed ID: 21558048
    [Abstract] [Full Text] [Related]

  • 9. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
    Park GC, Choi JA, Jang SJ, Jeong SH, Kim CM, Choi IS, Kang SH, Park G, Moon DS.
    Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259
    [Abstract] [Full Text] [Related]

  • 10. In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii.
    Ni W, Cui J, Liang B, Cai Y, Bai N, Cai X, Wang R.
    J Antibiot (Tokyo); 2013 Dec; 66(12):705-8. PubMed ID: 23981963
    [Abstract] [Full Text] [Related]

  • 11. Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.
    Cheng A, Chuang YC, Sun HY, Sheng WH, Yang CJ, Liao CH, Hsueh PR, Yang JL, Shen NJ, Wang JT, Hung CC, Chen YC, Chang SC.
    Crit Care Med; 2015 Jun; 43(6):1194-204. PubMed ID: 25793437
    [Abstract] [Full Text] [Related]

  • 12. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Liang CA, Lin YC, Lu PL, Chen HC, Chang HL, Sheu CC.
    Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
    [Abstract] [Full Text] [Related]

  • 13. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
    Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, Cheong HJ.
    J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
    [Abstract] [Full Text] [Related]

  • 14. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections.
    Ku K, Pogue JM, Moshos J, Bheemreddy S, Wang Y, Bhargava A, Campbell M, Khandker N, Lephart PR, Chopra T, Hayakawa K, Martin ET, Abreu-Lanfranco O, Dhar S, Kaye KS, Marchaim D.
    Am J Infect Control; 2012 Dec; 40(10):983-7. PubMed ID: 22440526
    [Abstract] [Full Text] [Related]

  • 15. Non-polymyxin-based combinations as potential alternatives in treatment against carbapenem-resistant Acinetobacter baumannii infections.
    Mohd Sazlly Lim S, Naicker S, Ayfan AK, Zowawi H, Roberts JA, Sime FB.
    Int J Antimicrob Agents; 2020 Oct; 56(4):106115. PubMed ID: 32721600
    [Abstract] [Full Text] [Related]

  • 16. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii.
    Niu T, Luo Q, Li Y, Zhou Y, Yu W, Xiao Y.
    Antimicrob Resist Infect Control; 2019 Oct; 8():52. PubMed ID: 30886705
    [Abstract] [Full Text] [Related]

  • 17. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
    Khawcharoenporn T, Pruetpongpun N, Tiamsak P, Rutchanawech S, Mundy LM, Apisarnthanarak A.
    Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
    [Abstract] [Full Text] [Related]

  • 18. Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: A multi-centre clinical experience.
    Russo A, Gullì SP, D'Avino A, Borrazzo C, Carannante N, Dezza FC, Covino S, Polistina G, Fiorentino G, Trecarichi EM, Mastroianni CM, Torti C, Oliva A.
    Int J Antimicrob Agents; 2024 Jul; 64(1):107190. PubMed ID: 38697579
    [Abstract] [Full Text] [Related]

  • 19. Successful treatment of skin and soft tissue infection due to carbapenem-resistant Acinetobacter baumannii by ampicillin-sulbactam and meropenem combination therapy.
    Hiraki Y, Yoshida M, Masuda Y, Inoue D, Tsuji Y, Kamimura H, Karube Y, Takaki K, Kawano F.
    Int J Infect Dis; 2013 Dec; 17(12):e1234-6. PubMed ID: 23791858
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis.
    Dinc G, Demiraslan H, Elmali F, Ahmed SS, Metan G, Alp E, Doganay M.
    Chemotherapy; 2013 Dec; 59(5):325-9. PubMed ID: 24525528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.